These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36066785)

  • 1. Lp(a): a New Pathway to Target?
    Nurmohamed NS; Kraaijenhof JM; Stroes ESG
    Curr Atheroscler Rep; 2022 Nov; 24(11):831-838. PubMed ID: 36066785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations for routinely testing for high Lp(a).
    Nurmohamed NS; Moriarty PM; Stroes ESG
    Curr Opin Lipidol; 2022 Jun; 33(3):213-218. PubMed ID: 35695619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent lipoprotein(a) trials.
    Wei T; Cho L
    Curr Opin Lipidol; 2022 Dec; 33(6):301-308. PubMed ID: 36345866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3.
    Malick WA; Goonewardena SN; Koenig W; Rosenson RS
    J Am Coll Cardiol; 2023 Apr; 81(16):1633-1645. PubMed ID: 37076218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for routinely testing for high lipoprotein(a).
    Nurmohamed NS; Moriarty PM; Stroes ES
    Curr Opin Lipidol; 2023 Aug; 34(4):174-179. PubMed ID: 35942815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
    Duarte Lau F; Giugliano RP
    JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
    Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
    J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
    Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy.
    Sosnowska B; Surma S; Banach M
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latest developments in the treatment of lipoprotein (a).
    Bos S; Yayha R; van Lennep JE
    Curr Opin Lipidol; 2014 Dec; 25(6):452-60. PubMed ID: 25318824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
    Kronenberg F; Mora S; Stroes ESG; Ference BA; Arsenault BJ; Berglund L; Dweck MR; Koschinsky M; Lambert G; Mach F; McNeal CJ; Moriarty PM; Natarajan P; Nordestgaard BG; Parhofer KG; Virani SS; von Eckardstein A; Watts GF; Stock JK; Ray KK; Tokgözoğlu LS; Catapano AL
    Eur Heart J; 2022 Oct; 43(39):3925-3946. PubMed ID: 36036785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a): the revenant.
    Gencer B; Kronenberg F; Stroes ES; Mach F
    Eur Heart J; 2017 May; 38(20):1553-1560. PubMed ID: 28329241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein(a).
    Kronenberg F
    Handb Exp Pharmacol; 2022; 270():201-232. PubMed ID: 34196811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.
    Boffa MB
    Curr Atheroscler Rep; 2016 Dec; 18(12):69. PubMed ID: 27761705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol.
    Yeang C; Karwatowska-Prokopczuk E; Su F; Dinh B; Xia S; Witztum JL; Tsimikas S
    J Am Coll Cardiol; 2022 Mar; 79(11):1035-1046. PubMed ID: 35300814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease.
    Tada H; Takamura M; Kawashiri MA
    J Atheroscler Thromb; 2019 Jul; 26(7):583-591. PubMed ID: 31061262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
    Vogt A
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
    Vuorio A; Watts GF; Kovanen PT
    Atherosclerosis; 2019 Feb; 281():25-30. PubMed ID: 30616181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lp(a): Addressing a Target for Cardiovascular Disease Prevention.
    Vasquez N; Joshi PH
    Curr Cardiol Rep; 2019 Jul; 21(9):102. PubMed ID: 31367887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein (a): When to Measure and How to Treat?
    Rhainds D; Brodeur MR; Tardif JC
    Curr Atheroscler Rep; 2021 Jul; 23(9):51. PubMed ID: 34235598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.